Premium
Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues
Author(s) -
Ratziu Vlad,
Caldwell Stephen,
NeuschwanderTetri Brent A.
Publication year - 2010
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.24042
Subject(s) - nonalcoholic steatohepatitis , medicine , metformin , insulin resistance , clinical trial , nonalcoholic fatty liver disease , intensive care medicine , insulin , steatohepatitis , disease , fatty liver
Insulin sensitizers are attractive candidate therapies for nonalcoholic steatohepatitis mainly because of the strong association between this disease and insulin resistance. This review provides a critical overview of the mechanisms of action, clinical trial results, and safety issues of metformin and glitazones in nonalcoholic steatohepatitis. It also highlights methodological challenges for trial design and proposes endpoints for future proof of principle, registrational, and postmarketing trials. (HEPATOLOGY 2010;52:2206‐2215)